Find a Tender · Contract
NP37719 Sevoflurane & Isoflurane
A public procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) via Find a Tender.
- —
- Award value
- —
- Tender value
- 3
- Suppliers
- 5
- Awards
- 1
- Notices
- Contract
- Stage
Overview
Supply of Sevoflurane & Isoflurane to NHS Scotland.
Key details
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- complete
- CPV classification
- 33600000 — Pharmaceutical products
- Currency
- GBP
- Total award value
- —
- Tender value
- —
- First published
- 12 Dec 2023
- Last updated
- 12 Dec 2023
Awards
5 awards recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| AbbVie Ltd | 08004972 | — | active | — |
| Baxter Healthcare Ltd | 00461365 | — | active | — |
| AbbVie Ltd | 08004972 | — | active | — |
| Baxter Healthcare Ltd | 00461365 | — | active | — |
| Piramal Critical Care | 05160306 | — | active | — |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
More from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
FAQs about this procurement
Who is the buyer for "NP37719 Sevoflurane & Isoflurane"?
NP37719 Sevoflurane & Isoflurane is a UK public-sector procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) via Find a Tender.
Has "NP37719 Sevoflurane & Isoflurane" been awarded?
Yes — 5 awards are recorded. The current lifecycle stage is "Contract".
Which suppliers are involved in "NP37719 Sevoflurane & Isoflurane"?
3 suppliers are linked: AbbVie Ltd, Baxter Healthcare Ltd, Piramal Critical Care.
When was "NP37719 Sevoflurane & Isoflurane" published?
It was first published on 12 Dec 2023 and last updated on 12 Dec 2023, across 1 notice.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable